Fut, nem toboroz1. fázis
A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor−Positive Breast Cancer
Key facts
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid és Valencia, SpanyolországSee the 7 sites
- Phase
- 1. fázis
Where in Spanyolország
- Hospital Universitari Vall d'HebronBarcelona, SpanyolországNo longer taking part
- Institut Catala D'oncologiaL'Hospitalet de Llobregat, SpanyolországNo longer taking part
- Hospital General Universitario Gregorio MarañónMadrid, SpanyolországNo longer taking part
- Hospital Universitario HM SanchinarroMadrid, SpanyolországNo longer taking part
- Hospital Universitario Ramón y CajalMadrid, SpanyolországNo longer taking part
- MD Anderson Cancer CenterMadrid, SpanyolországNo longer taking part
- Hospital Clinico Universitario de ValenciaValencia, SpanyolországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Genentech Inc.
- Trial code
- EU 2023-506700-12-00
- Record updated
- 2026. április 21.